### **BAUSCH** Health

## Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant

October 13, 2015

# Local Elected Officials & Business Leaders Joined Valeant Executives at South Carolina Plant

LAVAL, Quebec, Oct. 13, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that the company celebrated the production of the four billionth bottle of eye care products manufactured at Bausch + Lomb's Greenville Solutions Plant, with Valeant Chairman and Chief Executive Officer J. Michael Pearson joining elected officials, employees, and local business leaders on a tour of the South Carolina facility. Commemorative bottles

specially labeled to denote the batch containing the four billionth bottle were produced for the occasion.

The Bausch + Lomb solutions plant has been a staple of the Greater Greenville community for more than 30 years since opening in 1983. The plant employs a workforce of more than 500 employees who help to manufacture more than 30 essential medical products, which are then sent to a nearby shipping facility to be packaged and transported around the world. Among the top global Valeant brands manufactured at the Greenville facility include Biotrue<sup>®</sup> multi-purpose solution, ReNu<sup>®</sup> Solutions, and Boston<sup>®</sup> solutions for gas permeable contact lenses. Many of the Greenville Solutions Plant's employees have worked at the site for more than 10 years.

Additionally, Valeant and Bausch + Lomb executives announced a new, state-of-the-art, integrated line investment of approximately \$25 million. The expansion, coupled with a previously approved solutions-making investment, will add 40 million units of capacity – an overall increase of more than 20 percent. More than 30 new jobs will be created from the increase in capacity, with an expected \$7 million spent on local construction and engineering firms. Valeant is also committing to new investments of approximately \$90 million over the next two years, and approximately \$150 million over the next five years, which is expected to result in 150 to 200 new jobs in the next five years.

"Reaching this incredible milestone at Bausch + Lomb's Greenville Solutions Plant demonstrates the enormous impact that the facility has had across the globe," **said Pearson**. "Whether it's one of the hundreds of employees creating our top-of-the-line products, or a consumer who has bought one of our four billion bottles manufactured at this facility for his or her lens care needs, the work that is done here is essential to peoples' lives. We are incredibly proud of the employees in Greenville, who reflect the very best of Valeant Pharmaceuticals."

"Congratulations to the Bausch + Lomb Greenville Solutions Plant on your four billionth bottle, and to 32 years of bringing manufacturing jobs to the Upstate," said **Senator Lindsey Graham**.

"South Carolinians are grateful to have such an essential business in our state, and we look forward to many more years of success and positive community impact."

"Longstanding businesses in our community have provided valuable contributions to our thriving workforce," said **Senator Tim Scott**. "Being able to celebrate major production milestones underscores the dedication of these businesses in our state, and reinforces South Carolina's role as the center of our nation's manufacturing renaissance."

"Thank you to the Bausch + Lomb Greenville Solutions Plant for the invitation to celebrate the production of its four billionth bottle," said **Representative Trey Gowdy**. "For over thirty years, the Greenville Bausch + Lomb facility has continued to manufacture and export products worldwide, supporting hundreds of jobs in the Upstate. Congratulations on this achievement."

#### **About Valeant Pharmaceuticals International, Inc.**

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at

www.valeant.com

.

#### **About Bausch + Lomb**

Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries.

®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.


© 2015 Bausch & Lomb Incorporated.

#### **News Media Contacts:**

Laurie Little SVP, Investor Relations (949) 461-6002 or laurie.little@valeant.com

Kristy Marks
Manager, Product PR, Bausch + Lomb
(585) 338-8095 or
kristy.marks@bausch.com

Mike Schrader VP, Greenville Operations, Bausch + Lomb (864) 281-2545 or michael.schrader@bausch.com



http://photos.prnewswire.com/prnh/20151013/276471

To view the original version on PR Newswire, visit:

http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-celebrates-the-manufacturin g-of-four-billion-bottles-of-eye-care-products-at-bausch--lombs-greenville-solutions-plant-300158 902.html

SOURCE Valeant Pharmaceuticals International, Inc.





**Investor Inquiries** 

<u>ir@bauschhealth.com</u> 877-281-6642 514-856-3855 (Canada) LEGAL NOTICE PRIVACY POLICY

EMAIL ALERTS EMAIL PAGE

E RSS FEED

Media inquiries

<u>Corporate.communications@bauschhealth.com</u> 908-569-3692

Use of this site signifies your agreement to the Legal Notice and Privacy Policy. © 2025 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: <u>DO NOT SELL MY</u>

<u>PERSONAL INFORMATION</u>

